Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;12(2):210-216.
doi: 10.1016/j.ajur.2024.09.010. Epub 2025 Jan 25.

Robot-assisted partial nephrectomy for renal cell carcinoma: A narrative review of different clinical scenarios

Affiliations
Review

Robot-assisted partial nephrectomy for renal cell carcinoma: A narrative review of different clinical scenarios

Antonio Andrea Grosso et al. Asian J Urol. 2025 Apr.

Abstract

Objective: Nowadays robot-assisted partial nephrectomy (RAPN) represents the standard of care for clinical T1 (cT1) renal masses, providing similar oncological outcomes when compared to open or laparoscopic PN with advantages in terms of functional outcomes and lower perioperative comorbidity, when compared to radical nephrectomy.

Methods: We performed an extensive literature review of studies regarding RAPN, its evolution, technical aspects and applications, and new technological tools using different combinations of Medical Subject Headings terms "RAPN", "partial nephrectomy", "robot-assisted", "nephron-sparing surgery", "renal cell carcinoma", "complex renal masses", "endophytic renal masses", and "bilateral renal tumors".

Results: A consistent body of evidence was selected, including original articles, systematic reviews, meta-analyses, and clinical trials having RAPN as the central focus in adult patients, with all its technical nuances. We started our narrative review with a background on PN and its evolution toward the robotic era with a special spotlight on the extending indications for PN in large and highly complex renal masses. Our review continued with an overview of nephron-sparing surgery in bilateral and recurrent masses. RAPN for bilateral synchronous renal masses represents a challenging scenario with no formal recommendations provided by international guidelines and controversial management and decision-making. Additionally, we reported evidence on redo RAPN which seems to be safe and effective. A final overview of the available technological tools, and in particular on three-dimensional reconstruction was provided.

Conclusion: RAPN has been established as the standard of care for cT1 renal masses with an expanding spectrum of applications in different scenarios, including large (cT2), highly complex, and bilateral renal masses, as well as the surgical treatment of local recurrences after nephron-sparing surgery with acknowledged advantages in terms of functional outcomes and perioperative risk profiles while maintaining similar oncological outcomes when compared to open or laparoscopic PN and radical treatment.

Keywords: Bilateral tumor; Partial nephrectomy; Renal cell carcinoma; Robotics; Three-dimensional reconstruction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387. - PubMed
    1. Capitanio U., Bensalah K., Bex A., Boorjian S.A., Bray F., Coleman J., et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74–84. - PMC - PubMed
    1. Bukavina L., Bensalah K., Bray F., Carlo M., Challacombe B., Karam J.A., et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82:529–542. - PubMed
    1. Grosso A.A., Di Maida F., Tellini R., Viola L., Lambertini L., Valastro F., et al. Assessing the impact of socio-economic determinants on access to care, surgical treatment options and outcomes among patients with renal mass: insight from the universal healthcare system. Eur J Cancer Care. 2022;31 doi: 10.1111/ecc.13666. - DOI - PMC - PubMed
    1. Ljungberg B., Albiges L., Abu-Ghanem Y., Bedke J., Capitanio U., Dabestani S., et al. European Association of Urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82:399–410. - PubMed

LinkOut - more resources